Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study

Abstract

Etanercept was an effective and well-tolerated treatment in this real-life cohort of patients.

Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis

“…15,21,22 Etanercept was also shown to be an effective and well-tolerated treatment in a real-life cohort of 23 children with psoriasis. 8 In a randomised, double-blind, multicentre, phase III trial in children with chronic plaque psoriasis non-responsive to topical therapy, treatment with adalimumab 0.8 mg/kg was found to be safe and result in a significant improvement in PASI 75 scores, as compared to methotrexate, after 16 weeks. Patients in the adalimumab group also showed a non-significant improvement in PGA scores at 16 weeks as compared to the methotrexate group.…”

“…5,6 However, data are sparse on the efficacy and toxicity of systemic agents in the paediatric population. [6][7][8] Standardised guidelines are lacking, and few clinical trials have been conducted in children. 5,[9][10][11] Targeted therapies, including tumour necrosis factor alpha blockers (anti-TNFa agents) and ustekinumab, have recently been shown to be effective and safe as therapies for childhood psoriasis in controlled trials.…”

Etanercept biosimilar SB 4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry

“…Etanercept is a recombinant tumour necrosis factor (TNF)‐α soluble receptor fused to the Fc fragment of human IgG1 and the first TNF‐α inhibitor approved for the treatment of chronic plaque psoriasis in both adults and children . The etanercept biosimilar SB4 (Benepali ® , Biogen, Cambridge, MA, U.S.A.) has recently been approved based on the results of stringent comparability exercises designed to demonstrate similarity to the originator in terms of quality, biological activity, efficacy and safety .…”

Secukinumab for psoriasis in a patient with familial Mediterranean fever

“…Topical corticosteroids are typically recommended as first‐line therapy for mild to moderate psoriasis (Girolomoni et al, ), while patients with moderate or severe psoriasis may require systemic therapy in combination with topical drugs (Di Lernia et al, ). Biological drugs can be used to treat patients with moderate to severe psoriasis (Ceccarelli et al, ) including those with other immune‐mediated disorders (Guarneri, Russo, Mazzeo, & Cannavo, ).…”